Intraocular lens developer LensGen raised $7.3 million in a new round of equity funding, according to an SEC filing posted this week.
The Irvine, Calif.-based company develops the Juvene accommodating intraocular lens.
The Juvene lens is designed to potentially permanently restore clear and continuous vision at all distances for patients with cataracts and presbyopia, LensGen said. The company said the lens mimics the eye’s natural accommodation process to change shape and adjust focus, and can be implanted using current surgical techniques for intraocular lenses.
Money in the round came from 13 anonymous investors, with the 1st sale dated on May 1, 2017, according to the SEC filing. The company is looking to raise an additional $22.7 million before closing the funding round.
Earlier this month, LensGen said it closed a $21 million Series A financing round. The financing round was led by the corporate venture investment arm of Hoya Group and was joined by Relativity Healthcare Partners, the company said.